Memory B Cell and Other Immune Responses in Children Receiving Two Doses of an Oral Killed Cholera Vaccine Compared to Responses following Natural Cholera Infection in Bangladesh

Leung, Daniel T.; Rahman, Mohammad Arif; Mohasin, M.; Patel, Sweta; Aktar, Amena; Khanam, Farhana; Uddin, Taher; Riyadh, M. Asrafuzzaman; Saha, Amit; Alam, Mohammad Murshid; Chowdhury, Fahima; Khan, Ashraful Islam; Charles, Richelle C.; LaRocque, Regina C.; Harris, Jason B.; Calderwood, Stephen B.; Qadri, Firdausi; Ryan, Edward T.

doi:10.1128/cvi.00299-12

Cited by 10 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These vaccines are given in two or three doses depending on age and produce protective efficacy against the moderate and severe disease of between 60% -85%, for up to two to three years after vaccination. They are less effective in children below two years and produce a shorter duration of protection in these individuals (Leung et al, 2012). A field trial of the oral cholera vaccine was done in Mozambique, where two doses of Dukoral showed 78% protective efficacy against disease in a cholera outbreak.…”

Section: The Cholera Vaccinementioning

confidence: 99%

Childhood diarrhoeal diseases in developing countries

Ugboko

Nwinyi

Oranusi

et al. 2020

Heliyon

115

View full text Add to dashboard Cite

Diarrhoeal diseases collectively constitute a serious public health challenge globally, especially as the leading cause of death in children (after respiratory diseases). Childhood diarrhoea affecting children under the age of five accounts for approximately 63% of the global burden. Accurate and timely detection of the aetiology of these diseases is very crucial; but conventional methods, apart from being laborious and time-consuming, often fail to identify difficult-to-culture pathogens. The aetiological agent of an average of up to 40% of cases of diarrhoea cannot be identified. This review gives an overview of the recent trends in the epidemiology and treatment of diarrhoea and aims at highlighting the potentials of metagenomics technique as a diagnostic method for enteric infections.

show abstract

Section: The Cholera Vaccinementioning

confidence: 99%

Childhood diarrhoeal diseases in developing countries

Ugboko

Nwinyi

Oranusi

et al. 2020

Heliyon

115

View full text Add to dashboard Cite

show abstract

“…T cell responses have been demonstrated to be different after a natural V. cholerae infection and after vaccination, 20 and lower T cell and memory B cell responses induced by current OCVs might limit duration of protection after vaccination compared with immunity after natural infection and disease. 14 , 21 The addition of α-GalCer might be beneficial to induce long-term protection againt V. cholerae , particularly at the site of infection, after administration of OCVs. The efficacy of oral α-GalCer administration was also addressed in male C57BL/6 mice.…”

Section: Discussionmentioning

confidence: 99%

Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines

et al. 2019

View full text Add to dashboard Cite

Cholera is a severe diarrheal disease caused by the bacterium Vibrio cholerae (V. cholerae) that results in 3-4 million cases globally with 100,000-150,000 deaths reported annually. Mostly confined to developing nations, current strategies to control the spread of cholera include the provision of safe drinking water and improved sanitation and hygiene, ideally in conjunction with oral vaccination. However, difficulties associated with the costs and logistics of these strategies have hampered their widespread implementation. Specific challenges pertaining to oral cholera vaccines (OCVs) include a lack of safe and effective adjuvants to further enhance gut immune responses, the complex and costly multicomponent vaccine manufacturing, limitations of conventional liquid formulation and the lack of an integrated delivery platform. Herein we describe the use of the orally active adjuvant α-Galactosylceramide (α-GalCer) to strongly enhance intestinal bacterium-and toxin-specific IgA responses to the OCV, Dukoral ® in C57BL/6 and BALB/c mice. We further demonstrate the mucosal immunogenicity of a novel multi-antigen, singlecomponent whole-cell killed V. cholerae strain and the enhancement of its immunogenicity by adding α-GalCer. Finally, we report that combining these components and recombinant cholera toxin B subunit in the SmPill ® minisphere delivery system induced strong intestinal and systemic antigen-specific antibody responses.

show abstract

“…We counted the number of MBC ASC per well independently using two reviewers in a sample-blinded fashion with a stereomicroscope and averaged the counts. We applied previously determined criteria for inclusion in the analysis, excluding wells that failed stimulation, exhibited nonspecific stimulation, or were stimulated in response to the negative control [21].…”

Section: Isolation Of Peripheral Blood Mononuclear Cells (Pbmcs) and Mbc Enzyme-linked Immune Absorbent Spot Assaymentioning

confidence: 99%

A Co-abundant Gene Analysis for Identification of Gut Microbial Strains Associated with Immune Responses to Oral Cholera Vaccine

Heller

Banna

Kaisar

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundOral cholera vaccines (OCVs) are an important tool for reduction of the worldwide cholera burden, but some individuals who receive an OCV do not develop protective immune responses. The gut microbiota is a potential explanation for these differences. Components of the gut microbiota associated with differences in OCV response have not been identified.ResultsWe used metagenomic sequencing to identify predicted protein-coding genes in the gut microbiota at the time of OCV administration, and then measured immune responses to vaccination. Vaccine recipients were classified as OCV “responders” if they developed a postvaccination increase in memory B cell populations that produce IgA or IgG specific for cholera toxin and the V. cholerae O-specific polysaccharide. We next analyzed microbial genes seen at similar abundances across individual samples and classified these into co-abundant gene groupings (CAGs), and correlated CAGs with OCV responses. Next, to identify specific bacterial strains associated with OCV responses, we mapped CAGs to bacterial genomes and generated a “priority score” for each strain detected in the study population. This score reflects both the number of CAGs aligning to a specific bacterial genome and the strength of the association between the CAGs and the vaccine response. This strain-level analysis revealed relationships between the gut microbiota and immune response to OCV that were not detected at the genus or species level. Bacterial strains which produce short-chain fatty acids and those with sphingolipid-containing cell membranes were correlated with more robust immune responses to vaccination.ConclusionOur study demonstrates a method for translating metagenomic sequencing data into strain-specific results associated with a biological outcome. Using this approach, we identified strains for the study of bacterial-derived molecules or metabolites associated with immune responses; such agents might have potential utility as vaccine adjuvants.

show abstract

Memory B Cell and Other Immune Responses in Children Receiving Two Doses of an Oral Killed Cholera Vaccine Compared to Responses following Natural Cholera Infection in Bangladesh

Cited by 10 publications

References 0 publications

Childhood diarrhoeal diseases in developing countries

Childhood diarrhoeal diseases in developing countries

Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines

A Co-abundant Gene Analysis for Identification of Gut Microbial Strains Associated with Immune Responses to Oral Cholera Vaccine

Contact Info

Product

Resources

About